M. T. Seymour

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

M. Parmar, H. Wasan, G. Middleton, 2011, The Lancet.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

Accuracy of radiological staging in identifying high‐risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience

R. Gray, B. Warren, P. Quirke, 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

P. Quirke, J. Cheadle, G. Middleton, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

T. Hickish, M. Dobson, A. Wotherspoon, 2012, The Lancet. Oncology.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

S. Gwyther, S. Richman, J. Wadsley, 2013, The Lancet. Oncology.